FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387403338> ?p ?o ?g. }

• W4387403338 abstract "Blonanserin (BNS) had been undergoing post-market surveillance (PMS) since September 2018. Using the surveillance data, we did this analysis to assess the safety and effectiveness of different doses of BNS to explore a sufficient dose range of BNS in Chinese patients with schizophrenia (SZ).A 12-week, prospective, observational, single-arm, multicenter, open-label PMS was conducted. In this analysis, we divided the patients from PMS into low, medium to high, and high dose groups based on the dose of BNS they received, with medium to high dose group being the focus. The Brief Psychiatric Rating Scale (BPRS) scores at week 2 or 4, 6 or 8, and 12 were calculated to evaluate the effectiveness of BNS in improving psychiatric symptoms. The safety of BNS was reported as the incidence of adverse drug reactions.364 patients were included in the medium to high dose group, of which 321 completed the surveillance, with a dropout rate of 11.8%. The mean daily dose was 15.1 ± 1.92 mg. The BPRS total score was 50.1 ± 11.95 at baseline and decreased to 26.6 ± 7.43 at 12 weeks (P < 0.001). When compared with other groups, the median to high dose group achieved significantly more reduction in BPRS score at week 12 (P = 0.004 versus low dose and P = 0.033 versus higher dose). Extrapyramidal symptoms [EPS (46.4%)] were the most common adverse reactions in the medium to high group. The average weight gain during the surveillance was 0.5 ± 2.56 kg and prolactin elevation occurred in 2.2% patients. Most adverse reactions were mild.BNS at medium to high doses (mean 15.1 mg/d) significantly improved symptoms of SZ and was well-tolerated. Most ADRs were mild, and the likelihood of causing metabolic side effects and prolactin elevations was low. Medium to high dose of BNS is a more potent treatment choice for SZ.ChiCTR2100048734. Date of registration: 2021/07/15 (retrospectively registered)." @default.
• W4387403338 created "2023-10-07" @default.
• W4387403338 creator A5005872065 @default.
• W4387403338 creator A5006991265 @default.
• W4387403338 creator A5010302301 @default.
• W4387403338 creator A5010430615 @default.
• W4387403338 creator A5010538647 @default.
• W4387403338 creator A5026208453 @default.
• W4387403338 creator A5027689782 @default.
• W4387403338 creator A5030921116 @default.
• W4387403338 creator A5043869212 @default.
• W4387403338 creator A5046549558 @default.
• W4387403338 creator A5050015445 @default.
• W4387403338 creator A5051136100 @default.
• W4387403338 creator A5068070876 @default.
• W4387403338 creator A5068969552 @default.
• W4387403338 creator A5071817609 @default.
• W4387403338 creator A5074691262 @default.
• W4387403338 creator A5078094295 @default.
• W4387403338 creator A5082862848 @default.
• W4387403338 date "2023-10-06" @default.
• W4387403338 modified "2023-10-11" @default.
• W4387403338 title "Safety and effectiveness of oral medium to high dose blonanserin in patients with schizophrenia: subgroup analysis from a prospective, multicenter, post-marketing surveillance study in mainland China" @default.
• W4387403338 cites W162017141 @default.
• W4387403338 cites W1902957927 @default.
• W4387403338 cites W1963402089 @default.
• W4387403338 cites W2033372335 @default.
• W4387403338 cites W2049320250 @default.
• W4387403338 cites W2062327263 @default.
• W4387403338 cites W2136236608 @default.
• W4387403338 cites W2157369969 @default.
• W4387403338 cites W2792480682 @default.
• W4387403338 cites W2916226351 @default.
• W4387403338 cites W3025481414 @default.
• W4387403338 cites W4226237151 @default.
• W4387403338 cites W4293749019 @default.
• W4387403338 doi "https://doi.org/10.1186/s12991-023-00467-w" @default.
• W4387403338 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37803378" @default.
• W4387403338 hasPublicationYear "2023" @default.
• W4387403338 type Work @default.
• W4387403338 citedByCount "0" @default.
• W4387403338 crossrefType "journal-article" @default.
• W4387403338 hasAuthorship W4387403338A5005872065 @default.
• W4387403338 hasAuthorship W4387403338A5006991265 @default.
• W4387403338 hasAuthorship W4387403338A5010302301 @default.
• W4387403338 hasAuthorship W4387403338A5010430615 @default.
• W4387403338 hasAuthorship W4387403338A5010538647 @default.
• W4387403338 hasAuthorship W4387403338A5026208453 @default.
• W4387403338 hasAuthorship W4387403338A5027689782 @default.
• W4387403338 hasAuthorship W4387403338A5030921116 @default.
• W4387403338 hasAuthorship W4387403338A5043869212 @default.
• W4387403338 hasAuthorship W4387403338A5046549558 @default.
• W4387403338 hasAuthorship W4387403338A5050015445 @default.
• W4387403338 hasAuthorship W4387403338A5051136100 @default.
• W4387403338 hasAuthorship W4387403338A5068070876 @default.
• W4387403338 hasAuthorship W4387403338A5068969552 @default.
• W4387403338 hasAuthorship W4387403338A5071817609 @default.
• W4387403338 hasAuthorship W4387403338A5074691262 @default.
• W4387403338 hasAuthorship W4387403338A5078094295 @default.
• W4387403338 hasAuthorship W4387403338A5082862848 @default.
• W4387403338 hasBestOaLocation W43874033381 @default.
• W4387403338 hasConcept C118552586 @default.
• W4387403338 hasConcept C120665830 @default.
• W4387403338 hasConcept C121332964 @default.
• W4387403338 hasConcept C126322002 @default.
• W4387403338 hasConcept C197636746 @default.
• W4387403338 hasConcept C197934379 @default.
• W4387403338 hasConcept C2776412080 @default.
• W4387403338 hasConcept C2778528637 @default.
• W4387403338 hasConcept C2779727114 @default.
• W4387403338 hasConcept C61511704 @default.
• W4387403338 hasConcept C71924100 @default.
• W4387403338 hasConceptScore W4387403338C118552586 @default.
• W4387403338 hasConceptScore W4387403338C120665830 @default.
• W4387403338 hasConceptScore W4387403338C121332964 @default.
• W4387403338 hasConceptScore W4387403338C126322002 @default.
• W4387403338 hasConceptScore W4387403338C197636746 @default.
• W4387403338 hasConceptScore W4387403338C197934379 @default.
• W4387403338 hasConceptScore W4387403338C2776412080 @default.
• W4387403338 hasConceptScore W4387403338C2778528637 @default.
• W4387403338 hasConceptScore W4387403338C2779727114 @default.
• W4387403338 hasConceptScore W4387403338C61511704 @default.
• W4387403338 hasConceptScore W4387403338C71924100 @default.
• W4387403338 hasIssue "1" @default.
• W4387403338 hasLocation W43874033381 @default.
• W4387403338 hasLocation W43874033382 @default.
• W4387403338 hasOpenAccess W4387403338 @default.
• W4387403338 hasPrimaryLocation W43874033381 @default.
• W4387403338 hasRelatedWork W1985435777 @default.
• W4387403338 hasRelatedWork W2032712358 @default.
• W4387403338 hasRelatedWork W2063113598 @default.
• W4387403338 hasRelatedWork W2079637050 @default.
• W4387403338 hasRelatedWork W2355839613 @default.
• W4387403338 hasRelatedWork W2360155000 @default.
• W4387403338 hasRelatedWork W2388439346 @default.
• W4387403338 hasRelatedWork W2400434151 @default.
• W4387403338 hasRelatedWork W2462067835 @default.
• W4387403338 hasRelatedWork W53389649 @default.
• W4387403338 hasVolume "22" @default.
• W4387403338 isParatext "false" @default.

• next